Genitourinary Radiology

SNMMI: Botox may prevent debilitating dry mouth for some mCRPC patients
By Liz Carey
Research presented at the meeting addressed salivary gland toxicity associated with uptake of PSMA-targeted radioligand therapy.
June 24, 2025
2025 06 24 Dual Approach Mmrpc Thumbnail
Nuclidium presents phase I results for PSMA tracer at SNMMI
By AuntMinnie.com staff writers
Nuclidium presented positive data from the phase I clinical trial of its new copper-61 PET imaging agent for prostate cancer.
June 24, 2025
Prostate Cancer 2
Archeus Technologies nets ART-101 IND FDA clearance
By AuntMinnie.com staff writers
The company has received U.S. Food and Drug Administration (FDA) clearance of its ART-101 Investigational New Drug (IND) application.
June 20, 2025
Prostate 3 D
Clarity highlights first patient imaged in Amplify trial
By AuntMinnie.com staff writers
Clarity Pharmaceuticals has imaged the first patient in its phase III Amplify trial at XCancer in Omaha, NE.
May 29, 2025
Prostate Cancer 3 D Rendering 400 (1)
Covera Health expanding COE program to prostate imaging
By AuntMinnie.com staff writers
Covera Health is adding prostate imaging to its Radiology Centers of Excellence (COE) platform.
May 8, 2025
Prostate Cancer 3 D Rendering 400 (1)
ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
By Maryam Payne
Evaluating increased rib uptake on F-18 DCFPyL PET/CT in prostate cancer patients may lead to false positives.
April 28, 2025
Pet Ct Machine
Clarius launches Clarius Prostate AI
By AuntMinnie.com staff writers
Clarius Mobile Health is launching the Clarius Prostate AI tool for prostate volume measurement.
April 25, 2025
Clarius Prostate AI measures prostate volume from ultrasound exams.
Microultrasound could be alternative to MRI for prostate biopsy
By Amerigo Allegretto
Microultrasound may be a suitable alternative to MRI for image-guided prostate biopsy.
March 26, 2025
Ultrasound Probe2 400
Quibim’s QP-Prostate cleared for diagnosing prostate cancer
By AuntMinnie.com staff writers
Quibim has received clearance from the U.S. Food and Drug Administration (FDA) for use of its QP-Prostate MRI software to help detect and diagnose prostate cancer.
March 21, 2025
Prostate Imaging2
FDA greenlights Telix NDA for prostate imaging agent Gozellix
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for Telix's TLX007-CDx for prostate cancer imaging.
March 21, 2025
Fda Logo V2 Social
DL algorithm targeting prostate cancer demonstrates clinical impact
By Liz Carey
Per participant, a deep-learning (DL) algorithm demonstrated increased specificity of 64.8% compared with radiologists at 21.3%.
March 12, 2025
MRI scans show two areas of clinically significant prostate cancer in a 65-year-old man with a prostate-specific antigen level of 8.23 ng/mL. Images are (A, E) axial T2-weighted images, (B, F) axial diffusion-weighted images obtained with a b value of 1500 sec/mm2, (C, G) axial apparent diffusion coefficient images, and (D, H) lesion masks generated by the deep learning algorithm (DLA) on T2-weighted images. The DLA detected a lesion in the right posteromedial peripheral zone of the apex (D), which was assigned as Prostate Imaging Reporting and Data System (PI-RADS) 4. A radiologist also detected the lesion and assigned it PI-RADS 4 (arrow in A-C). A lesion in the right anterior transition zone (H) was detected by the DLA, which was assigned PI-RADS 4. The radiologist did not detect the lesion (arrow in E-G). Both lesions were confirmed as prostate cancer with Gleason grade group 2. Caption and image courtesy of RSNA.
bpMRI, mpMRI show comparable NPV for prostate cancer
By Kate Madden Yee
Biparametric MRI (bpMRI) and multiparametric MRI (mpMRI) show similar negative predictive value (NPV) in identifying prostate cancer.
March 7, 2025
Prostate Cancer 3 D Rendering
Page 1 of 93
Next Page